(Total Views: 439)
Posted On: 07/24/2021 7:04:22 PM
Post# of 154090
Re: Riztheinvestor #97208
One must ask, why would the 13D be fighting for a "no name" company and why would CNBC even have any interest in this fight?
They actually answered that question in the article:
So, basically, it's a diamond in the rough company and CYDY should not be a "no name" company and is worth much more than now. They essentially say this in the article with:
All of this is IMHO, but this article in a mainstream press CNBC is good for us because it goes under Any Press is Good Press.
They actually answered that question in the article:
Quote:
The group believes leronlimab is an extraordinary drug and states that CYDY’s growth hinges on the immediate success of leronlimab.
So, basically, it's a diamond in the rough company and CYDY should not be a "no name" company and is worth much more than now. They essentially say this in the article with:
Quote:
If the company is successful in receiving U.S. Food and Drug Administration (FDA) approval for leronlimab, the group of investors believes many lives will be saved, and tremendous value will be created for the company’s stockholders.
All of this is IMHO, but this article in a mainstream press CNBC is good for us because it goes under Any Press is Good Press.
(9)
(0)
